Introduction
============

Colorectal cancer (CRC) is one of the most common malignant diseases worldwide. A previous study showed that are high rates of incidence and disease-associated mortality for CRC ([@b1-ol-0-0-11982]). The development of effective screening methods to detect cancer is vital as it is necessary for early diagnosis and therapy. To provide novel biological insight and advances in therapy, the molecular mechanisms underlying malignant tumor occurrence and progression are being investigated, with the aim of developing more effective therapies for CRC ([@b2-ol-0-0-11982]).

MicroRNAs (miRNAs or miRs) are small non-coding RNA molecules, which are endogenous and 18--25 nucleotides in length. The function of miRNAs is to modulate the expression of target mRNAs at a post-transcriptional level and the mechanism of action is by inhibiting mRNA translation or inducing mRNA degradation by binding to a target site ([@b3-ol-0-0-11982],[@b4-ol-0-0-11982]). The target sites may be in the 3′ untranslated region (3′-UTR), coding region and the promoter ([@b5-ol-0-0-11982],[@b6-ol-0-0-11982]). It has been reported that miRNAs regulate the expression of \>60% of human protein-encoding genes ([@b7-ol-0-0-11982]). These genes take part in numerous biological processes, including cell proliferation, differentiation, apoptosis, invasion and autophagy ([@b8-ol-0-0-11982]--[@b10-ol-0-0-11982]).

miR-424-5p, located at Xq26.3, it is differentially expressed in tumor tissues and normal tissues adjacent to tumors, and it serves different biological functions ([@b11-ol-0-0-11982]). The expression levels of miR-424-5p are increased in pancreatic ([@b12-ol-0-0-11982]) and gastric cancer ([@b13-ol-0-0-11982]); however, the expression levels are decreased in hepatocellular carcinoma, esophageal squamous cell carcinoma and cervical cancer ([@b14-ol-0-0-11982]--[@b16-ol-0-0-11982]). The expression and function of miR-424-4p in CRC requires to be reported.

The present study analyzed the miRNA expression profiles using miRNA sequencing data from The Cancer Genome Atlas (TCGA; <http://cancergenome.nih.gov/>) and determined the cyto-biological effects of miR-424-5p on human CRC cells.

Materials and methods
=====================

### miRNA array in TCGA for heatmap analysis

Data from TCGA, which is a large-scale cancer genome project that provides genome sequencing data of 33 types of cancer (<http://cancergennme.nih.gov/>) ([@b17-ol-0-0-11982]), were analyzed. The data included microRNA sequencing, RNA-sequencing and clinical datasets for various cancer types. In the present study, miRNA array data were obtained from TCGA for heatmap analysis. The sequencing data of miRNAs from 11 adjacent control samples and 619 CRC tissue samples were downloaded from TCGA database and the expression matrix of the miRNAs was aggregated.

### Patients and samples

CRC and paired non-tumor adjacent tissue samples, as well as clinicopathological data were collected from patients who underwent radical resection between July 2016 and March 2018 at The First Hospital of Hebei Medical University (Shijiazhuang, China). A total of 59 pairs of CRC and non-tumor adjacent tissues were used for the experiments. The adjacent tissue samples were obtained ≥5 cm from the edge of the tumor. The present study was approved by the Ethics Committee of the First Affiliated Hospital of Hebei Medical University (Shijiazhuang, China; approval nos. 2013106 and 2016004). All patients provided written informed consent for the use of their samples. Following surgical removal, tissues were immediately frozen in liquid nitrogen and stored at −80°C. The pathological diagnosis of all cancer tissue samples was adenocarcinoma or mucinous carcinoma, all the tissues were pathologically confirmed as cancerous or normal. The clinicopathological data of the patients are presented in [Table I](#tI-ol-0-0-11982){ref-type="table"}.

### Cell culture and transfection

The human CRC cell line SW480 was obtained from Professor Xiao-feng Sun (American Type Culture Collection). Detection of mycoplasma free cell was performed using a Mycoplasma Monitoring kit (Vazyme Biotech Co., Ltd.). Cells were cultured in Dulbecco\'s modified Eagle\'s medium (DMEM; Gibco; Thermo Fisher Scientific, Inc.) containing 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.) and 1% penicillin-streptomycin. All cells were cultured in standard growth medium at 37°C in a humidified atmosphere with 5% CO~2~. miR-424-5p mimic (50 nM; cat. no. HmiR-SN0494), miR-424-5p inhibitor (50 nM; cat. no. HmiR-AN0494-SN-10), mimic control (50 nM; cat. no. CmiR-SN0001-SN) and inhibitor control (50 nM; cat. no. CmiR-AN0001-SN) were purchased from GeneCopoeia, Inc. Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) was used to perform transfection according to the manufacturer\'s protocol.

### Cell proliferation and colony formation assay

To investigate the role of miR-424-5p in the development of CRC, the cell viability was evaluated using a Cell Counting Kit (CCK)-8 assay (Vazyme Biotech Co., Ltd.), according to the manufacturer\'s instructions. SW480 cells were transfected with miR-424 mimic, mimic control, miR-424 inhibitor or inhibitor control for 48 h. Logarithmically growing cells were then seeded in 10-cm normal cell culture dishes (3,000 cells/dish) and incubated for 14 days in medium with 10% FBS that was changed every week, and cells were cultured at 37°C. Subsequently, the colonies were stained with crystal violet (0.5%) for 1 h at room temperature and the number of colonies was counted manually. The colony formation ability was determined in triplicate in tissue culture dishes.

### Cell migration and invasion assay

The cell motility capacities were determined using a wound-healing assay and Transwell assay. The wound-healing assay was performed in 6-well culture plates; SW480 cells were seeded in the plate at a density of 50×10^5^ cells/well in culture medium. Following transfection for 48 h, the cells reached 100% confluence and confluent monolayers were scratched with a sterile micro-pipette tip (200 µl), followed by washing with PBS to remove floating cells. The width of the scratch was then measured at 0, 24, 48 and 72 h of incubation in serum-free medium. A total of three independent experiments were performed.

For migration assays, transfected cells (20×10^5^ per well) in 100 µl serum-free DMEM were plated in the top chamber of a Transwell system (Corning, Inc.), which consisted of 12 wells with an 8.0-µm pore diameter polycarbonate membrane insert. The insert was placed onto a 24-well plate, the bottom chambers of which were filled with 600 µl DMEM with 10% FBS as a chemoattractant. Following 48 h of incubation, the cells remaining on the upper surface of the filter were removed by scraping with a cotton swab, while the cells that had transgressed to the lower surface of the filter were fixed with Diff Quik Fix (mainly methanol) for 2 min, followed by staining with Diff Quik I (eosin) for 2 min and staining with Diff Quik II (mainly methylene blue) for 45 sec. All Diff Quik products were purchased from Zhuhai Beisuo Biology Co, Ltd (BA-4150; [www.baso.com.cn](www.baso.com.cn)). A total of three independent experiments were performed.

For invasion experiments, transfected cells (20×10^5^ per well) in 200 µl FBS-free DMEM were cultured in the top chamber of a Transwell system that included a Matrigel Invasion Chambers (cat. no. 354480; Corning, Inc.), while the bottom well contained 800 µl medium with FBS. Following incubation for 48 h, cells that had migrated to the lower side of the chamber were stained as specified above. A total of three independent experiments were performed.

### Reverse transcription-quantitative PCR (RT-qPCR)

Total RNA was extracted from the frozen tissues using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer\'s protocol. The concentration and purity of all RNA samples were detected using a NanoDrop ND-2000 spectrophotometer (NanoDrop Technologies; Thermo Fisher Scientific, Inc.).

cDNA synthesis of miRNA was performed using the All-in-One miRNA First-Strand cDNA Synthesis Kit (QP013; GeneCopoeia, Inc.), according to the manufacturer\'s protocol. qPCR was performed using an All-in-One™ miRNA qPCR kit (QP015; GeneCopoeia, Inc.) with a Roche LightCycler 480 II Real-Time PCR system (Roche Diagnostics) according to the manufacturer\'s protocol. The sequence-specific primers for mature miR-424-5p (cat. no. HmiRQP0494) and the U6 internal control (cat. no. HmiRQP9001), as well as the Uni-miR qPCR Primer were purchased from GeneCopoeia, Inc. The relative expression of miR-424-5p was calculated using the 2^−ΔΔCq^ method with normalization to the expression of U6 ([@b18-ol-0-0-11982]).

A total of 1 µg RNA was reverse-transcribed into cDNA using the PrimeScript RT kit (Takara Bio Inc.) for mRNA detection, at 37°C for 15 min, and 85°C for 5 sec. qPCR was subsequently performed using the Power SYBR^®^ Green Master mix (Applied Biosystems; Thermo Fisher Scientific, Inc.), according to the manufacturer\'s protocol (step 1: 95°C for 10 min; step 2 for 40 cycles: 95°C for 15 sec, 60°C for 1 min). The following primer pairs were used for the qPCR: WNT6, Forward: 5′-CGTAGGGCGGTCACGATG-3′ and reverse: 5′-AACTGGAACTGGCACTCTCG-3′; WNT11, forward: 5′-TCTTTGGGGTGGCACTTCTC-3′ and reverse: 5′-TGCCGAGTTCACTTGACGAG-3′; DVL1, forward: 5′-CCTCACTAACCAGCTCCGTG-3′ and reverse: 5′-ACGTGTGTGTACAGCCAGTC-3′; RAC3, forward: 5′-CCTTCGAGAATGTTCGTGCC-3′ and reverse: 5′-TTCACAGAGCCAATCTCCCG-3′; FZD9, forward: 5′-GAACCCCACACACCTCTAGC-3′ and reverse: 5′-CTAATGAGCCTCACGGGGTC-3′; SFRP, forward: 5′-GCTGCACATGAAGAATGGCG-3′ and reverse: 5′-GTAGTAGAGGGAGCAGGGGT-3′; FZD2, forward: 5′-GCGAAGCCCTCATGAACAAG-3′ and reverse: 5′-CTCCGTCCTCGGAGTGGTTC-3′ and GAPDH, forward: 5′-ACCCACTCCTCCACCTTTG-3′ and reverse: 5′-CTCTTGTGCTCTTGCTGGG-3′. The expression levels were normalized to the internal reference gene GAPDH and quantified using the 2^−ΔΔCq^ method ([@b18-ol-0-0-11982]).

### Transcriptome sequencing and differential expression analysis

To identify small RNAs and the target genes, SW480 colon cancer cells were transfected with miR-424-5p mimic and mimic control, and following transfection for 48 h, the total RNA was extracted for transcriptome sequencing. A total amount of 3 µg RNA per sample was used for the RNA sample preparations. Sequencing libraries were generated using the NEBNext^®^ Ultra™ RNA Library Prep kit for Illumina^®^ (New England Biolabs) following the manufacturer\'s protocol and index codes were added to assign sequences to each sample. Library quality was assessed on the Agilent Bioanalyzer 2100 system (Agilent Technologies, Inc.). The clustering of the index-coded samples was performed on a cBot Cluster Generation system using the TruSeq PE Cluster kit v3-cBot-HS (Illumia, Inc.) according to the manufacturer\'s protocol. Following cluster generation, the library preparations were sequenced on an Illumina Hiseq platform (Illumina, Inc.).

Raw data (raw reads) in fastq format were first processed through in-house perl scripts. Reference genome and gene model annotation files were downloaded from the genome website directly. An index of the reference genome was built using Hisat2 v2.0.5 and the Fragments Per Kilobase of transcript per Million mapped reads (FPKM) of each gene were calculated based on the length of the gene and reads count mapped to this gene. The FPKM results were uploaded to Baidu (<https://pan.baidu.com/s/1PxiK87dIbhfgZUL2y9nqZg>) (extraction code, djau). Differential expression analysis of miR-424-5p mimic/mimic control was performed using the DESeq2 package of R (1.16.1). The resulting P-values were adjusted using the Benjamini and Hochberg approach for controlling the false discovery rate. DEGs were screened from three independent transcriptome sequencing by DESeq2 and genes with an adjusted P\<0.05 were considered as DEGs.

Subsequently, disease oncology analysis using the Database for Annotation, Visualization and Integrated Discovery (DAVID, <http://david.ncifcrf.gov/>) and Kyoto Encyclopedia of Genes and Genomes Orthology Based Annotation System (<http://kobas.cbi.pku.edu.cn/index.php>), gene ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses of the DEGs were performed using the clusterProfiler package of R.

### Statistical analysis

For continuous variables, values are expressed as the median ± standard deviation or the median and 25th and 75th percentiles (interquartile range). All experiments were performed in triplicates. Differences between groups were analyzed using the Mann-Whitney U-test, two-way analysis of variance and correction for multiple comparisons using the Sidak statistical hypothesis test or an unpaired Student\'s t-test. P\<0.05 was considered to indicate a statistically significant difference. SPSS v21.0 (IBM, Corp.) and GraphPad Prism v7.0 (GraphPad Software, Inc.) were used for statistical analysis.

Results
=======

### miR-424-5p is upregulated in human CRC tissues

Heatmap analysis of the miRNA expression profiles of 619 CRC and 11 normal colorectal tissues was first performed using the TCGA database. From the series matrix files, 276 DEGs were identified, among which 180 were upregulated and 96 were downregulated ([Table SI](#SD1-ol-0-0-11982){ref-type="supplementary-material"}). The top 30 upregulated miRNAs are presented in a heatmap in [Fig. 1A](#f1-ol-0-0-11982){ref-type="fig"}. To further confirm these results, the expression of miR-424-5p in 59 pairs of CRC tissue and corresponding non-tumor colorectal tissue samples was analyzed. The expression of miR-424-5p in the CRC tissues was significantly higher compared with that in the corresponding non-tumor colorectal tissues (P=0.0056; [Fig. 1B](#f1-ol-0-0-11982){ref-type="fig"}). The clinicopathological characteristics \[age (median=62, 25% percentile (P25)=50.5, P75=72.5); sex (male:female=35:24); Dukes\' stage (A,B:C,D=32:27); pathological type (adenocarcinoma: Mucinous carcinoma=39:20); depth of invasion (T1,T2:T3,T4=23:36); location (colon:rectum=32:27); lymph node metastasis (absent:present=30:29); distant metastasis (absent:present=49:10)\] of the patients are presented in [Table I](#tI-ol-0-0-11982){ref-type="table"}. In summary, the results revealed that mR-424-5p is upregulated in CRC tissues.

### miR-424-5p expression is associated with Dukes\' stage, depth of invasion and pathological type of CRC

The expression levels of miR-424-5p in CRC tissues were significantly increased in Dukes\' stage C.D compared with those in Dukes\' stage A.B \[median (interquartile range), 32.45 (5.696-117.8) vs. 2.695 (1.518-43.65); P=0.0159; [Fig. 2A](#f2-ol-0-0-11982){ref-type="fig"}\]. The expression of miR-424-5p in CRC tissues was also increased in adenocarcinoma compared with mucinous carcinoma \[12.38 (1.905-170.1) vs. 4.848 (1.641-26.72); P=0.0451; [Fig. 2B](#f2-ol-0-0-11982){ref-type="fig"}\]. Regarding infiltration depth, the expression levels of miR-424-5p in CRC tissues were upregulated in T3.T4 stage \[33.65 (2.191-117.4)\] compared with T1.T2 stage \[3.77 (1.47-14.67); P=0.0450; [Fig. 2C](#f2-ol-0-0-11982){ref-type="fig"}\].

### Overexpression of miR-424-5p promotes and suppression of miR-424-5p inhibits CRC cell proliferation

To investigate the role of miR-424-5p in the development of CRC, the cell viability was evaluated using a Cell Counting Kit (CCK)-8 assay. The SW480 cells were successfully transfected with miR-424-5p mimic (8.35±0.086) or mimic control (1±0.015), and miR-424-5p inhibitor (0.083±0.009) or inhibitor control (1±0.015; [Fig. 3A and B](#f3-ol-0-0-11982){ref-type="fig"}). Following transfection for 24 h, a CCK-8 assay was performed and miR-424-5p expression was measured. The expression of miR-424-5p and cell viability was increased following transfection of miR-424-5p mimic as compared that in the mimic control-transfected SW480 cells at 24, 48, 72 and 96 h ([Fig. 3C](#f3-ol-0-0-11982){ref-type="fig"}). Following transfection with miR-424-5p inhibitor, the expression of miR-424-5p and the viability of SW480 cells was significantly decreased as compared with that in the inhibitor control-transfected group at 48, 72 and 96 h ([Fig. 3D](#f3-ol-0-0-11982){ref-type="fig"}). A colony formation assay was also performed with SW480 cells transfected with miR-424-5p mimic or mimic control and miR-424-5p inhibitor or inhibitor control. Colony formation by SW480 cells transfected with miR-424-5p mimic was significantly increased compared with that in the mimic control group ([Fig. 3E](#f3-ol-0-0-11982){ref-type="fig"}). In the miR-424-5p inhibitor-transfected SW480 group, the colony formation was significantly decreased as compared with that in the inhibitor control group ([Fig. 3F](#f3-ol-0-0-11982){ref-type="fig"}). These results indicated that the miR-424-5p expression is positively associated with CRC cell proliferation.

### Overexpression of miR-424-5p promotes and suppression of miR-424-5p inhibits the migration and invasion of CRC cells

SW480 cells were transfected with miR-424-5p mimic or mimic control and inhibitor or inhibitor control for 48 h and then subjected to a wound-healing assay. The results revealed that miR-424-5p overexpression promoted CRC cell migration, while silencing of miR-424-5p markedly inhibited CRC cell migration (P\<0.05; [Fig. 4A and B](#f4-ol-0-0-11982){ref-type="fig"}). Subsequently, Transwell assays were used to examine the effects of miR-424-5p on SW480 cell migration and invasion. Overexpression of miR-424-5p significantly promoted, while silencing of miR-424-5p significantly inhibited the migration of CRC cells (P\<0.05; [Fig. 4C and D](#f4-ol-0-0-11982){ref-type="fig"}). Blue staining represents migrating/invading cells. As presented in [Fig. 4E](#f4-ol-0-0-11982){ref-type="fig"}, SW480 cells transfected with miR-424-5p mimic exhibited a significantly higher invasive capacity. However, those transfected with miR-424-5p inhibitor had a significantly lower invasive capacity compared with those transfected with the control ([Fig. 4F](#f4-ol-0-0-11982){ref-type="fig"}). Therefore, miR-424-5p was indicated to have a stimulatory effect on the migration and invasion of CRC cells.

### Identification and functional characterization of DEGs from the transcriptome sequencing of SW480 cells transfected with miR-424-5p mimic and control

Transcriptome sequencing revealed DEGs between SW480 cells transfected with miR-424-5p mimic and those transfected with the control. These DEGs comprised 1,322 upregulated genes ([Table SII](#SD1-ol-0-0-11982){ref-type="supplementary-material"}) and 980 downregulated genes ([Table SIII](#SD1-ol-0-0-11982){ref-type="supplementary-material"}), including protein-coding genes and non-coding genes ([Fig. 5A](#f5-ol-0-0-11982){ref-type="fig"}). The top 20 upregulated protein-coding genes are presented in [Table II](#tII-ol-0-0-11982){ref-type="table"} and the top 20 downregulated protein-coding genes are presented in [Table III](#tIII-ol-0-0-11982){ref-type="table"}. GO analyses revealed that the majority of the DEGs were significantly enriched in 'serine hydrolase activity', 'serine-type peptidase' and 'endopeptidase activity' ([Fig. 5B](#f5-ol-0-0-11982){ref-type="fig"}). Disease ontology functional enrichment analysis of these DEGs revealed that they were accumulated in different diseases, including skin disease, infertility and colonic diseases ([Fig. 5C](#f5-ol-0-0-11982){ref-type="fig"}). Signaling pathway analysis indicated that the DEGs were enriched in the 'Wnt signaling pathway' ([Fig. 5D](#f5-ol-0-0-11982){ref-type="fig"}).

Nuclear factor of activated T cells 5, Wnt family member 6 (WNT6), adenomatous polyposis coli, nuclear factor of activated T cells 3, low-density lipoprotein receptor-related protein 6, WNT2B, WNT11, dishevelled segment polarity protein 1 (DVL1), Rac family small GTPase 3 (RAC3), frizzled class receptor 9 (FZD9), secreted frizzled-related protein 5 (SFRP5), frizzled class receptor 2 (FZD2), Rho-associated coiled-coil containing protein kinase 1 (ROCK1) and ROCK2 were enriched in the Wnt signaling pathway; therefore, the expression of these genes was analyzed by RT-qPCR. The expression levels of WNT6, WNT11, DVL1, RAC3, FZD9, SFRP5 and FZD2 were downregulated in miR-424-5p mimic-transfected cells compared with the control cells ([Table IV](#tIV-ol-0-0-11982){ref-type="table"}).

Discussion
==========

The expression of miR-424-5p has been reported to be dysregulated in human cancer and may either be up- or downregulated in tumor tissues depending on the tumor type ([@b19-ol-0-0-11982]). miR-424-5p was observed to be upregulated in certain types of cancer, including esophageal squamous cell carcinoma ([@b15-ol-0-0-11982]), gastric cancer ([@b13-ol-0-0-11982]), pancreatic cancer ([@b12-ol-0-0-11982]) and tongue squamous cell carcinoma ([@b20-ol-0-0-11982]), while it was downregulated in others, including epithelial ovarian cancer ([@b11-ol-0-0-11982]), endometrial carcinoma ([@b21-ol-0-0-11982]), cervical cancer ([@b22-ol-0-0-11982]), lung cancer ([@b23-ol-0-0-11982]), chronic myeloid leukemia ([@b24-ol-0-0-11982]), hepatocellular carcinoma ([@b25-ol-0-0-11982]) and bladder cancer ([@b26-ol-0-0-11982]). The present study indicated that miR-424-5p was increased in CRC tissues and its association with clinicopathological data were determined. The expression of miR-424-5p was higher in advanced Dukes\' stages of CRC (compared with less advanced stages of CRC), deeper invasion depth of tumors (compared with T1&T2 invasion depth of CRC) and adenocarcinoma (compared with mucinous carcinoma). miR-424-5p expression was previously reported to be associated with muscle invasion, high pathological grade, lymph node involvement and distant metastasis in bladder cancer ([@b26-ol-0-0-11982]). Various studies have reported that the abnormal expression of miR-424-5p is associated with different clinicopathological characteristics in different tumor types. All of these studies suggested that miR-424-5p has an important role in tumor progression.

A large number of studies have indicated that the same miRNA may serve different biological roles in different types of cancer cell by acting as either an oncogene or tumor suppressor. miR-424-5p has been demonstrated to serve as a tumor suppressor in most types of human cancer, including hepatocellular carcinoma ([@b27-ol-0-0-11982],[@b28-ol-0-0-11982]). miR-424-5p has been reported to suppress tumor cell proliferation, migration and invasion through downregulating the expression of c-Myb, catenin beta interacting protein 1 (ICAT) and Akt3. miR-424-5p may function as a tumor suppressor in endometrial carcinoma cells by targeting E2F transcription factor (E2F)7 ([@b21-ol-0-0-11982]). Similarly, miR-424-5p acts as an oncogene by targeting various genes in cervical cancer ([@b16-ol-0-0-11982],[@b29-ol-0-0-11982]) and breast cancer ([@b19-ol-0-0-11982]). miR-424-5p has been reported to be aberrantly expressed in several cancer types and to act as a tumor suppressor when downregulated in these cancer types. However, miR-424-5p promotes cell proliferation by targeting Smad3 via the transforming growth factor-β signaling pathway in gastric cancer ([@b13-ol-0-0-11982]). Various studies have indicated that RNA exhibits different expression and biological functions in different tumor tissue types. The present study demonstrated that miR-424-5p promotes the migration and invasion of the SW480 CRC cell line.

It is understood that miRNA leads to the alteration of mRNA by binding to the 3′-UTR of the gene, leading to the regulation of posttranscriptional gene expression by inhibiting the translation or degradation of mRNA. However, the exact mechanisms, including all of the target genes and targeting interactions, of how miRNAs regulate their target genes remain to be fully elucidated ([@b30-ol-0-0-11982]). miR-424-5p were also able to supress thousands of target genes expression, including the famous cancer related genes c-Myb, ICAT, Akt3 and E2F3 etc., downregulating of those genes could suppress hepatocellular carcinoma cell proliferation, migration and invasion ([@b19-ol-0-0-11982]). miRNAs are involved in a number of other oncogenic or carcinogenic networks, which leads to the regulation of several mRNAs. For instance, RAS-responsive element-binding protein (RREB1) and mutant KRAS repress miR-143-5p and the miR-145-5p promoter, and KRAS and RREB1 are targets of miR-145, revealing a feedback mechanism that increases the effect of RAS signaling ([@b31-ol-0-0-11982]). By performing a sequencing analysis and bioinformatics analysis of the results, the present study demonstrated that miR-424-5p regulates multiple genes. These genes are enriched in different signaling pathways and located in different cell types. Signaling pathway analysis indicated that the DEGs were enriched in 'endocytosis', 'regulation of actin cytoskeleton' and 'Wnt signaling pathway'.

Of note, the present study had certain limitations. For instance, only real-time PCR was used to detect the expression of miR-424-5p and no *in situ* hybridization (ISH) was employed. ISH is a complex technique and its advantage is that paraffin sections may be used. This technology is frequently used when paraffin sections are available ([@b32-ol-0-0-11982]). When total RNA is extracted from fresh tissue, PCR is more convenient than that ISH to examine the expression of miRNA. However, the intracellular position of miR-424-5p expression cannot be indicated using RT-qPCR.

In conclusion, the present study demonstrated that miR-424-5p, as a key candidate miRNA, was involved in the development of CRC. In addition, miR-424-5p regulated gene expression profiles and pathways of CRC, including the *WNT6, WNT11, DVL1, RAC3, FZD9, SFRP5* and *FZD2* genes. It was also demonstrated to a certain extent that the occurrence and development of tumors is the result of the common action of multiple genes. These candidate genes and pathways may be novel therapeutic targets and biomarkers for CRC.
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![Expression of miR-424-5p is upregulated in human CRC tissues. (A) Heat-map analysis of the top 30 upregulated miRNAs in 619 CRC and 11 normal colorectal tissues from The Cancer Genome Atlas database. The green/black/red color indicates low/medium/high miRNA expression. (B) miR-424-5p expression was determined in 59 CRC tissues (median=6.12, P25=1.87, P75=65.12) and adjacent normal tissues (median=3.29, P25=0.51, P75=19.84) by RT-qPCR analysis. The inter-quartile ranges were shown in the box diagram. \*P\<0.05 *vs.* adjacent normal tissues, according to the Mann-Whitney U-test. miRNA/miR, microRNA; CRC, colorectal cancer; hsa, *Homo sapiens*; P25, 25% percentile; P75, 75% percentile.](ol-20-04-11982-g00){#f1-ol-0-0-11982}

![Expression of miR-424-5p is associated with the differentiation and pathological type of CRC. (A) miR-424-5p expression in CRC tissues by Dukes\' staging (C,D vs. A,B). (B) miR-424-5p expression in mucinous carcinoma vs. adenocarcinoma. (C) miR-424-5p expression in CRC tissues by infiltration depth (T stage; T3, T4 vs. T1,T2). \*P\<0.05 according to the Mann-Whitney U-test. miR, microRNA.](ol-20-04-11982-g01){#f2-ol-0-0-11982}

![Effects of miR-424-5p on the proliferation of colorectal cancer cells. (A and B) The relative expression levels of miR-424-5p were detected by PCR in SW480 cells transfected with (A) miR-424-5p mimic or mimic control and (B) miR-424-5p inhibitor or inhibitor control. (C and D) Viability of SW480 cells transfected with (C) miR-424-5p mimic or mimic control and (D) miR-424-5p inhibitor or inhibitor control. (E and F) Colony formation ability of SW480 cells transfected with (E) miR-424-5p mimic or mimic control and (F) miR-424-5p inhibitor or inhibitor control. The significance of the difference between the two groups was determined by Student\'s t-test in A, B, E and F and by two-way analysis of variance in C and D. \*P\<0.05 vs. control. miR, microRNA.](ol-20-04-11982-g02){#f3-ol-0-0-11982}

###### 

Effects of miR-424-5p on the migration and invasive capability of colorectal cancer cells at 20× magnification. (A and B) Cell migration (scratch wound assay) was determined in SW480 cells transfected with (A) miR-424-5p mimic and mimic control or (B) miR-424-5p inhibitor and inhibitor control. (C and D) Cell migration was determined in SW480 cells transfected with (C) miR-424-5p mimic and mimic control or (D) miR-424-5p inhibitor and inhibitor control. (E and F) Cell invasion capability was determined in SW480 cells transfected with (E) miR-424-5p mimic and mimic control or (F) miR-424-5p inhibitor and inhibitor control. Values are expressed as the mean ± standard deviation of three independent experiments. \*P\<0.05 vs. control. miR, microRNA.
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![Identification and functional characterization of DEGs from the transcriptome sequencing in the SW480 cells transfected with miR-424-5p mimic and mimic control. (A) Volcano plot of the DEGs between the miR-424-5p mimic- and mimic control-transfected SW480 cells from transcriptome sequencing, including 1,322 upregulated genes (red dots, fold change \>2 and P\<0.05) and 980 downregulated genes (green dots, fold change ≤2 and P\<0.05). (B) Gene ontology analyses revealed that most of the DEGs were significantly enriched in serine hydrolase activity, serine-type peptidase and endopeptidase activity. (C) Disease ontology analysis of the DEGs. The DEGs were enriched in different diseases, including skin disease, infertility and colonic disease. The size of dots indicates the counts of DEGs. (D) Signaling pathway analyses using the Kyoto Encyclopedia of Genes and Genomes indicated that DEGs were enriched in signal transduction MAPK signaling pathway. The size of the dots indicates the counts of DEGs. miR, microRNA; DEG, differentially expressed gene; VEGF, vascular endothelial growth factor; TGF, transforming growth factor.](ol-20-04-11982-g05){#f5-ol-0-0-11982}

###### 

Clinicopathological characteristics of the patients with colorectal cancer (n=59).

  Variable                Value, n   miR-424-5p expression     P-value^[a](#tfn1-ol-0-0-11982){ref-type="table-fn"}^
  ----------------------- ---------- ------------------------- -------------------------------------------------------
  Age, years                                                   0.4995
    \<65                  36         11.505 (1.895, 105.238)   
    ≥65                   23         7.311 (1.986, 58.081)     
  Sex                                                          0.3716
    Male                  35         12.381 (2.042, 105.420)   
    Female                24         6.503 (1.618, 97.400)     
  Dukes\' stage                                                0.0159
    A,B                   32         2.695 (1.518, 43.650)     
    C,D                   27         32.450 (5.696, 117.800)   
  Pathological type                                            0.0451
    Adenocarcinoma        39         12.380 (1.905, 170.100)   
    Mucinous carcinoma    20         4.848 (1.641, 26.720)     
  Depth of invasion                                            0.0450
    T1,T2                 23         3.770 (1.470, 14.670)     
    T3,T4                 36         33.650 (2.191, 117.400)   
  Location                                                     0.5943
    Colon                 32         7.090 (1.916, 97.400)     
    Rectum                27         9.318 (1.905, 117.800)    
  Lymph node metastasis                                        0.6488
    Absent                30         7.075 (1.811, 104.900)    
    Present               29         9.318 (1.967, 108.600)    
  Distant metastasis                                           0.1495
    Absent                49         6.635 (1.854, 95.460)     
    Present               10         33.490 (8.706, 116.200)   

According to Mann-Whitney U-test. Values are expressed as the median (interquartile range). miR, microRNA.

###### 

Top 20 upregulated protein-coding differentially expressed genes (miR-424-5p mimic/mimic control, P\<0.05).

  Gene name      Log~2~ (fold-change)   Chromosome   Gene description
  -------------- ---------------------- ------------ ---------------------------------------------------------------
  SLC10A5        6.529                  8            Solute carrier family 10 member 5
  C11orf42       6.404                  11           Chromosome 11 open reading frame 42
  FGL2           6.404                  7            Fibrinogen-like 2
  B3GAT2         6.269                  6            Beta-13-glucuronyltransferase 2
  PSG9           6.119                  19           Pregnancy-specific beta-1-glycoprotein 9
  PKD2L2         5.951                  5            Polycystic kidney disease 2-like 2
  GCKR           5.951                  2            Glucokinase (hexokinase 4) regulator
  VWA5A          5.951                  11           Von Willebrand factor A domain containing 5A
  FRRS1          5.951                  1            Ferric-chelate reductase 1
  SENP3-EIF4A1   5.951                  17           SENP3-EIF4A1 readthrough (NMD candidate)
  GREB1L         5.762                  18           Growth regulation by estrogen in breast cancer-like
  COL23A1        5.762                  5            Collagen type XXIII α 1
  MRAP           5.762                  21           Melanocortin 2 receptor accessory protein
  SLC22A9        5.762                  11           Solute carrier family 22 (organic anion transporter) member 9
  CYP26C1        5.762                  10           Cytochrome P450 family 26 subfamily C member 1
  SLC46A2        5.762                  9            Solute carrier family 46 member 2
  RP11-166B2.1   5.762                  16           Putative NPIP-like protein LOC729978
  GPR182         5.544                  12           G protein-coupled receptor 182
  PCDHGB5        5.544                  5            Protocadherin gamma subfamily B 5
  TAL1           5.544                  1            T cell acute lymphocytic leukemia 1

###### 

Top 20 downregulated protein-coding differentially expressed genes (miR-424-5p mimic/mimic control, P\<0.05).

  Gene name   Log~2~ (fold-change)   Chromosome   Gene description
  ----------- ---------------------- ------------ ----------------------------------------------
  CGB5        −6.41484               19           Chorionic gonadotropin beta polypeptide 5
  FAM209A     −6.26472               20           Family with sequence similarity 209 member A
  ABI3        −6.09713               17           ABI family member 3
  SLC6A4      −5.9075                17           Solute carrier family 6 member 4
  NANOS2      −5.9075                19           Nanos homolog 2 (Drosophila)
  AGXT        −5.9075                2            Alanine-glyoxylate aminotransferase
  CLEC17A     −5.9075                19           C-type lectin domain family 17 member A
  IL1R2       −5.68911               2            Interleukin 1 receptor type II
  SPATA3      −5.68911               2            Spermatogenesis associated 3
  REG3A       −5.68911               2            Regenerating family member 3 α
  PCED1B      −3.98055               12           PC-esterase domain containing 1B
  OMP         −3.78942               11           Olfactory marker protein
  TPO         −3.68344               2            Thyroid peroxidase
  ERN2        −3.30883               16           Endoplasmic reticulum to nucleus signaling 2
  BEND6       −3.30883               6            BEN domain containing 6
  ADGRD1      −3.15871               12           Adhesion G protein-coupled receptor D1
  GSTM3       −3.06686               1            Glutathione S-transferase mu 3 (brain)
  ADGRE1      −3.06686               19           Adhesion G protein-coupled receptor E1
  USHBP1      −2.97446               19           Usher syndrome 1C binding protein 1
  CCL3        −2.76975               17           Chemokine (C-C motif) ligand 3

###### 

Expression of genes of the Wnt signaling pathway.

  Gene name   Fold-change   P-value   Gene description
  ----------- ------------- --------- ----------------------------------------
  WNT6        0.2845772     0.00002   Wnt family member 6
  WNT11       0.43327208    0.00421   Wnt family member 11
  DVL1        0.45380582    0.00614   Dishevelled segment polarity protein 1
  RAC3        0.45782965    0.00737   Rac family small GTPase 3
  FZD9        0.46584114    0.00921   Frizzled class receptor 9
  SFRP5       0.47657406    0.01022   Secreted frizzled-related protein 5
  FZD2        0.48708141    0.01351   Frizzled class receptor 2

Fold change: miR-424-5p mimic/mimic control.

[^1]: Contributed equally
